Oxford Biomedica Share Discussion Threads

[harry s truman] 12/10/2022 15:50

Excellent find there Marcus. I think your x-man alter ego (Bloodhounderene) has just discovered one of the Lenti announcements for Q4.

Cabaletta announce a new target for clinical trials and the existing agreement with us (second link) says "The LSA also allows for the parties to initiate additional projects in the future".

So licence for another indication / target and then the fees to develop and supply it.

In size it's obviously not going to be a Serum "we'd like a large bioreactor for a decade please" type of deal, but if it makes another million quid then every little helps (as someone once said).

[andymunchkin] 12/10/2022 14:20

mrBaDger uReCon tisWill test the BerzinskyBearD poinT@ 1oop?

[marcusl2] 12/10/2022 13:58

Hopefully more work for OXB



Cabaletta Bio Announces CABA-201, a Newly Designed CD19-Targeting CAR T Cell Therapy Engineered to Address a Broad Range of Autoimmune Diseases Cabaletta Bio
Tue, Oct 11, 2022, 07:00 am ET -

[harry s truman] 12/10/2022 13:44

Not all criminals wear the eye mask, the stripy jumper and carry a bag with swag written on it...

[marcusl2] 12/10/2022 10:37

Just reading about El Lilly`s woes.

More than a year after Eli Lilly received a subpoena centered on quality control snafus and alleged document tampering in New Jersey, U.S. drug inspectors have turned up a fresh batch of problems at the same site.


$1 billion acquisition of New York-based Prevail Therapeutics in 2020, which has three gene-based therapies in phase 1/2 trials. The lead candidate is PR001 for patients with Parkinson’s disease who have GBA1 mutations

[philh75] 12/10/2022 01:48

#4055 - Well now that seems a high risk approach, $250m+$500m to bring it all in house in 2-3 years with a payback of either $5b (or maybe $1b depending on who has their sales estimates right) - what could possibly go wrong?.

It puts our homology jv investment at the more sensible end of the spectrum! Buying an already working plant, with its own people that know what they are doing, incentivise them to bring in new business and get into a new vector and geographical main market.

Nice to see confirmation that lenti is in such demand though!

[harry s truman] 11/10/2022 20:43

Oxford Biomedica (OXB:LN) (OXBDF) PT Raised to GBP11.10 at RBC Capital
October 11, 2022 3:12 AM EDT Send to a Friend
RBC Capital analyst Charles Weston raised ...



It's a funny old world really isn't it?

The OXB share price keeps getting hit down and RBC raise their valuation by a quid.

[harry s truman] 11/10/2022 16:31

Catch,

No need to apologise and just to clarify I wasn't trying to attribute any of that to you, basically all I was doing was trying to find some common ground to agree on with the areas of market perception / market concerns - and I think those are pretty much just what has been written in the series of Times articles.

The Times loved us during the pandemic, but seem to be rather less enthusiastic of late.

I'm certain that Homology wasn't the only candidate they looked at partnering with, but remember it wasn't just the building and location they were after, they wanted IP which provided a very good AAV vector to go alongside LentiVector.

When Kyri talks about looking at what they could do, then he was obviously very impressed with the technology. With regard to due diligence, I wonder how that works with a new joint venture? I realise that if you were taking someone over in an amicable way, then they would show the accounts and the order book, but it wasn't that sort of deal. I would imagine (I don't know) that the technical scrutiny would be what took longest here.

There are some extremes of views knocking about here and whilst I don't think anybody on this BB takes the badger view seriously (they are criminals / they are liars / you are mugs / this is going bust / they will be bankrupt / etc.) there are many saner people who have genuine worries which are much more difficult to pin down (as I think I might have proved last night).

I appreciate that I'm at the other end of the same scale, but I often wonder how a scenario so bad has become "everybody knows" when it's really difficult to pin down what the dreadful part is.

Stuart always wants to talk about that "earnings before" acronym (i.e. we will more or less breakeven over H2), when I think we all know that's just a comparisons metric for the analysts which doesn't mean an awful lot to us as shareholders.

What I'm interested in is the profit / loss after tax, which will be something like a 10 or 15m loss this full year, but remember all these forecasts for the following years are also based on what we have now.

What are the chances that everything will stay the same? i.e. no new manufacturing contracts, nothing partnered out, no vaccine work, T-Charge, etc.

Anything new and it all changes. I think it's very difficult to predict, but there are a few people who have bricked themselves into a corner now whilst I'm just waiting for what OXB are going to announce this quarter.

I agree wholeheartedly with your last paragraph :)

[marcusl2] 11/10/2022 16:03

1st CAR-T/TCR-T
(Bristol Myers Squibb)

Undisclosed Phase I



OVARIAN CANCER AND MESOTHELIOMA

TCR2 Therapeutics/BMS



classical Hodgkin lymphoma (cHL)

Tessa Therapeutics
Collaborator:
Bristol-Myers Squibb


Juno/BMS Multiple Myeloma


Juno B-Cell Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia


Juno Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

[marcusl2] 11/10/2022 15:43

2nd CAR-T (Novartis)
Cancer (multiple) Phase I




significant potential remains for cell therapies to penetrate the CLL market due to the high unmet need for end-stage refractory patients



Novartis-backed Penn study proposes boosting CAR-T responses in CLL by waking up 'war weary' T cells7



BET turns down the expression of the CAR (chimeric antigen receptor). When they inhibited BET with a small-molecule drug called JQ1, T-cell exhaustion dropped and they were able to increase the production of CAR-T cells.

What’s more, the JQ1 boosted levels of certain cytokines and chemokines—proteins made by immune cells that previous studies had shown were key to the success of CAR-T in some CLL patients.


manufactured with a new process. CAR-T cells will be investigated in combination with ibrutinib in chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) and as single agent in diffuse large B-cell lymphoma (DLBCL) and in adult acute lymphoblastic leukemia (ALL). Phase 1 Overall status Recruiting.


A First-in-Human Study of YTB323, a Novel, Autologous CD19-Directed CAR-T Cell Therapy Manufactured Using the Novel T-Charge TM platform, for the Treatment of Patients (Pts) with Relapsed/Refractory (r/r) Diffuse Large B-Cell Lymphoma (DLBCL)

[catch007] 11/10/2022 10:52

Harry, apologies I was away for the weekend and have only read your post today.

Firstly, we shouldn't ever come to blows for having differing opinions at times on strategy, that is simply healthy debate when we both wish to see OXB prosper.

I haven't mentioned the AZ contract in my posts however the loss of the volume and income naturally had a material impact on the company. All covid companies took a knock as the pandemic came to an apparent end though I do not and never have classed OXB as a covid play as it has a broad and deep core offering with a rich pipeline.

The market was spooked by a deal imho OXB should never have done taking a stable business into a pure risk play and creating uncertainty. I personally believe that the leadership got it very wrong with Homology and it has destroyed the share price The speed of the deal highlighted a lack of commercial due diligence. Whilst there are lots of rational reasons given to defend the deal and the huge future potential the share price would be a lot higher if OXB had walked away imho. Borrowing at 10%+ to shore up finances is also an expensive cost that may not have been necessary. The old adage if something looks to good to be true it usually is comes to mind.

Anyway, it is now up to OXB management to show the market the value it has created with the deal and in time it could be the gamechanger they projected. I would be very happy to see this happen and see loyal shareholders rewarded.

[marcusl2] 11/10/2022 08:46

Some of our Pharma companies could be next on the shopping list!

Telegraph;A plunge in the pound this year has brought a rush of American buyers hoping to snap up prime London homes with tens of millions in dollar discounts.

[marcusl2] 11/10/2022 08:32

It would be nice if Axo–Lenti–PD got going again.

[badger60] 11/10/2022 07:09

Are we going to see 3 quid share price broken? There's nothing inspirational coming from the company to signal a reversal.
Has anyone bought Windrush yet, and if so at what price, and how long is the lease?
It would be encouraging to hear about some substantive deals being struck......you know the ones that pay the bills and give shareholders a dividend.
At this rate, each share could well be worth a brick ot two.

[badger60] 11/10/2022 01:44

Interesting reading......or maybe not.......OXB 52 week share price ..........317p (today's sp)...1606p (52 weeks ago)

[badger60] 11/10/2022 00:32

FIXX closed up at 1.49 USDps.....up 3 cents.

[harry s truman] 10/10/2022 21:09

Thanks for the reply steeplejack, but you still haven't told me what's wrong with OXB, just an explanation that I can't see what's wrong with OXB, which to be honest isn't a lot of help.

From what you have just written then I assume you're a technical investor and that's great - so the news is in the chart therefore you don't need to know what the issue is.

Of course I'm on the fundamentals side, so I do read all that they churn out and I honestly don't know what the "big" problem is.

Consolation is that our huge holders have followed me down. Some have bought more. Roch bought an amount which I've never seen from an OXB insider, which makes me think that it's not as bad as painted.

I will tell you one thing for sure and that is when OXB has indicated an extremely active Q4 it must be someone with pretty deep pockets who is willing to go short against that.

[dominiccummings] 10/10/2022 20:55

You mean the following gigabit?

"Kymriah to have less growth over the coming quarters and years and potentially even decline as our two competitors build out their second-line DLBCL program,”


So POTENTIALLY EVEN decline..... but likely continue to grow.

[dominiccummings] 10/10/2022 20:09

Yes Mr President. The market seems to have no idea that these 'deals' are more than an initial 'up front'. Many, perhaps not all, commit revenues to OXB for initial design work, manufacturing of trial product, then providing trials don't fail, further work up to full production.
We have a number of such client 'deals' each broadly with increasing revenues.
What is not to like?